Cargando…

Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals

SIMPLE SUMMARY: Chronic Hepatitis C virus (HCV) represents the main etiological factor for hepatocellular carcinoma (HCC) in developed countries. The introduction of direct-acting antivirals (DAAs) improved the eradication of the hepatitis C virus (HCV) but not the reduction in the incidence of HCV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabral, Loraine Kay D., Grisetti, Luca, Pratama, Muhammad Yogi, Tiribelli, Claudio, Pascut, Devis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179595/ https://www.ncbi.nlm.nih.gov/pubmed/35681679 http://dx.doi.org/10.3390/cancers14112700

Ejemplares similares

Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals
por: Pascut, Devis, et al.
Publicado: (2019)

Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
por: Pascut, Devis, et al.
Publicado: (2020)

Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and Their Clinical Implications
por: Pascut, Devis, et al.
Publicado: (2020)

Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma
por: Sukowati, Caecilia H. C., et al.
Publicado: (2021)

HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development
por: Pascut, Devis, et al.
Publicado: (2021)

Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients
por: Pascut, Devis, et al.
Publicado: (2020)

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer
por: Masadah, Rina, et al.
Publicado: (2021)

MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma
por: Grisetti, Luca, et al.
Publicado: (2022)

Circulating microRNA Associated to Different Stages of Liver Steatosis in Prader–Willi Syndrome and Non-Syndromic Obesity
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2017)

Correction: Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2018)

Silencing efficacy prediction: a retrospective study on target mRNA features
por: Pascut, Devis, et al.
Publicado: (2015)

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
por: Cabral, Loraine Kay D., et al.
Publicado: (2020)

Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma
por: Pascut, Devis, et al.
Publicado: (2019)

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma
por: Sukowati, Caecilia HC, et al.
Publicado: (2012)

Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma
por: Sukowati, Caecilia H. C., et al.
Publicado: (2018)

The Relevance of SOCS1 Methylation and Epigenetic Therapy in Diverse Cell Populations of Hepatocellular Carcinoma
por: Cabral, Loraine Kay D., et al.
Publicado: (2021)

Repeated double cross-validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients
por: Gurian, Elisa, et al.
Publicado: (2020)

PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma
por: Sukowati, Caecilia, et al.
Publicado: (2023)

Proteome profiling identifies circulating biomarkers associated with hepatic steatosis in subjects with Prader-Willi syndrome
por: Pascut, Devis, et al.
Publicado: (2023)

Clinical Significance of Apurinic/Apyrimidinic Endodeoxyribonuclease 1 and MicroRNA Axis in Hepatocellular Carcinoma
por: Mangiapane, Giovanna, et al.
Publicado: (2023)

A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients
por: Pascut, Devis, et al.
Publicado: (2019)

Network Analysis for the Discovery of Common Oncogenic Biomarkers in Liver Cancer Experimental Models
por: Cabral, Loraine Kay D., et al.
Publicado: (2023)

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct‐acting antivirals
por: Tachi, Yoshihiko, et al.
Publicado: (2017)

Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals
por: Syed, Taseen, et al.
Publicado: (2018)

Bilirubin-Induced Transcriptomic Imprinting in Neonatal Hyperbilirubinemia
por: Llido, John Paul, et al.
Publicado: (2023)

Differences in circulating microRNA signature in Prader–Willi syndrome and non-syndromic obesity
por: Pascut, Devis, et al.
Publicado: (2018)

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents
por: Kuftinec, Gabriela, et al.
Publicado: (2018)

Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals
por: Mercan-Stanciu, Adriana, et al.
Publicado: (2022)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
por: Leal, Cassia, et al.
Publicado: (2023)

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals
por: Rusie, Daniel, et al.
Publicado: (2022)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
por: Matsumae, Takayuki, et al.
Publicado: (2023)

Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals
por: Nguyen, Kelvin, et al.
Publicado: (2017)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u0kqt1fvk6kalh16ci0pucfa5u